Theravida, Inc.
Records under this name other than the patents Theravida, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Showing 1 to 6 of 6 · Back to Theravida, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,666,894 | Therapy for the treatment of disease Term ended Term ended Aug 28, 2026 · From the USPTO record | Term ended | Term ended Aug 28, 2026 | From the USPTO record |
| US 8,470,864 | Compositions and methods for the treatment of overactive bladder Term ended Ended no later than Aug 28, 2026 · From the USPTO record | Term ended | Ended no later than Aug 28, 2026 | From the USPTO record |
| US 9,132,124 | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder Lapsed on the fee record Ended Sep 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 15, 2023 | From the USPTO record |
| US 8,940,763 | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder Lapsed on the fee record Ended Jan 27, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jan 27, 2023 | From the USPTO record |
| US 7,781,472 | Therapy for the treatment of disease Lapsed on the fee record Ended Aug 24, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 24, 2022 | From the USPTO record |
| US 9,744,157 | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder Lapsed on the fee record Ended Aug 29, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 29, 2021 | From the USPTO record |